Document is current
Any future updates will be listed below
-
Authors
Saya, Sibel https://orcid.org/0000-0002-4796-6852
Chondros, Patty https://orcid.org/0000-0003-0393-8734
Abela, Anastasia https://orcid.org/0000-0003-2172-3294
Mihalopolous, Cathrine https://orcid.org/0000-0002-7127-9462
Chatterton, Mary Lou https://orcid.org/0000-0003-4902-9448
Gunn, Jane https://orcid.org/0000-0001-8836-7525
Chen, Timothy F. https://orcid.org/0000-0003-4189-8403
Polasek, Thomas M. https://orcid.org/0000-0003-1008-5223
Dettmann, Elise https://orcid.org/0009-0002-0775-4051
Brooks, Rachel https://orcid.org/0000-0002-8484-335X
King, Michelle https://orcid.org/0000-0002-3508-6559
Spencer, Luke https://orcid.org/0000-0003-4153-9048
Alphonse, Pavithran https://orcid.org/0000-0002-7238-685X
Milton, Shakira https://orcid.org/0000-0002-8510-6351
Ramsay, Georgia https://orcid.org/0000-0002-9408-8028
Siviour, Zoe https://orcid.org/0000-0001-8573-9979
Liew, Jamie https://orcid.org/0000-0002-9578-1078
Ly, Philip https://orcid.org/0000-0002-9828-6750
Thoenig, Matthew https://orcid.org/0000-0002-2059-4753
Seychell, Raushaan
La Rocca, Floriana
Hesson, Luke B.
Mejias, Nydia
Sivertsen, Terri
Galea, Melanie Anne
Bousman, Chad https://orcid.org/0000-0001-6303-8696
Emery, Jon https://orcid.org/0000-0002-5274-6336
-
Funding
Funding for this research was provided by:
MRFF (MRF1200060)
- License Information
-
More Information
Article History
Received: 1 May 2023
Accepted: 6 May 2023
First Online: 19 May 2023
Declarations
:
: The PRESIDE Trial has been approved by the UoM HREC and received institutional governance and sponsorship authorisation via the UoM Research Governance Office before commencement.The University of Melbourne Ethics Committee ID number: 20626.Services Australia ID number: RMS1620.
: Not applicable. No identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results. Informed consent materials are attached as supplementary materials.
: Sonic Healthcare (with Translational Software) currently has a commercially available pharmacogenomic test. To mitigate this conflict of interest, Sonic Healthcare and Translational Software will not have contact with GPs or participants. Identification of GPs and participants will be kept confidential within the PRESIDE study team. Chad Bousman is the founder and CEO of Sequence2Script Inc.
